Retatrutide vs GLP-1 and GIP: Understanding the Differences

EvergreenMedicalClinic
Jul 21
4 min read

What Is Retatrutide?

Obesity is now recognised as a chronic medical condition influenced by genetics, hormones, metabolism, lifestyle, and environmental factors. As research continues to advance, scientists are developing medicines that target the body's natural hormone pathways involved in appetite and energy balance.

One investigational medicine receiving increasing attention is retatrutide.

Retatrutide is currently being studied as a potential treatment for obesity and certain metabolic conditions. Although early clinical trial results have been encouraging, it has not been approved for routine clinical use in many countries, including Malaysia, at the time of writing.

This article explains what retatrutide is, how it works, and what current research suggests.

What Makes Retatrutide Different?

Unlike earlier medicines that target one or two hormone receptors, retatrutide is designed to activate three different hormone receptors involved in metabolism.

These include:

GLP-1 receptor
GIP receptor
Glucagon receptor

For this reason, retatrutide is commonly referred to as a triple receptor agonist.

Researchers are studying whether activating these three pathways together may improve weight management and metabolic health more effectively than targeting fewer pathways alone.

Understanding the Mechanism of Action

To understand retatrutide, it helps to first understand how the body regulates weight.

After eating, your digestive system releases several hormones that communicate with the brain, pancreas, liver, muscles, and fat tissue.

These hormones help regulate:

Hunger
Fullness
Blood sugar
Energy use
Fat storage

Retatrutide is designed to mimic three naturally occurring hormones simultaneously.

1. GLP-1: Helping You Feel Full

GLP-1 (Glucagon-Like Peptide-1) is released after meals.

It helps regulate appetite by:

Increasing feelings of fullness
Reducing hunger
Slowing stomach emptying
Supporting insulin release when blood sugar rises
Reducing glucagon secretion when appropriate

Many currently approved weight management medicines work through the GLP-1 pathway because of its established role in appetite regulation.

2. GIP: Supporting Metabolic Function

GIP (Glucose-Dependent Insulinotropic Polypeptide) is another hormone produced after eating.

Researchers now recognise that GIP has a broader role than previously thought.

It may help:

Improve insulin response
Support blood sugar regulation
Influence fat metabolism
Enhance the effects of GLP-1 when both pathways are activated

This is one reason dual GLP-1/GIP therapies have become an important area of obesity medicine.

3. Glucagon: Increasing Energy Expenditure

The third pathway targeted by retatrutide is the glucagon receptor.

Many people associate glucagon only with raising blood sugar.

However, researchers have found that glucagon also plays an important role in regulating energy metabolism.

Activation of the glucagon receptor may:

Increase energy expenditure
Encourage the body to use stored energy
Support fat metabolism

Scientists believe this additional pathway may complement the appetite-reducing effects of GLP-1 and GIP.

Why Are Researchers Interested in Combining All Three?

Obesity is influenced by multiple biological systems rather than a single hormone.

Each hormone affects different aspects of metabolism.

Hormone	Primary Role
GLP-1	Reduces appetite and promotes fullness
GIP	Supports insulin response and metabolic regulation
Glucagon	Increases energy expenditure and influences fat metabolism

Rather than focusing on appetite alone, triple receptor agonists are being studied for their potential to influence several aspects of energy balance at the same time.

Researchers are continuing to investigate whether this combined approach may offer additional benefits compared with therapies that target one or two hormone pathways.

What Does Current Research Show?

Early clinical studies have reported encouraging findings regarding weight reduction and improvements in metabolic health among participants receiving retatrutide.

Researchers are also evaluating its potential effects on:

Type 2 diabetes
Prediabetes
Fatty liver disease
Cardiovascular risk factors
Insulin resistance

While these findings are promising, larger studies and regulatory review are still ongoing.

Results from clinical trials do not guarantee that a medicine will receive regulatory approval or become suitable for every patient.

Is Retatrutide Available in Malaysia?

At the time of writing, retatrutide is an investigational medicine and is not approved for routine clinical use in Malaysia.

Availability and regulatory approval may differ between countries as additional evidence is reviewed by health authorities.

Patients should be cautious of products marketed as retatrutide outside legitimate clinical research settings, as their quality, safety, and authenticity may not be verified.

Is Retatrutide Better Than Current Treatments?

At present, it is too early to conclude that retatrutide is superior to currently approved therapies.

Although early research has generated considerable scientific interest, direct comparisons between different medicines require careful evaluation of:

Effectiveness
Safety
Side effects
Long-term outcomes
Individual patient characteristics

The most appropriate treatment depends on a person's overall health, medical history, treatment goals, and the therapies approved and available in their country.

Frequently Asked Questions

Is retatrutide available in Malaysia?

At present, retatrutide has not been approved for routine clinical use in Malaysia. It is NOT registered with Malaysia's Drug Control Authority (DCA). It is illegal to sell or import in the country.

Is retatrutide the same as GLP-1?

No. Retatrutide targets three hormone receptors—GLP-1, GIP, and glucagon—whereas GLP-1 medicines target only the GLP-1 receptor.

Why is retatrutide receiving attention?

Researchers are studying whether activating three hormone pathways simultaneously may improve weight management and metabolic health. However, additional research and regulatory review are still required.

Should I wait for retatrutide?

No, If you are living with obesity or related health conditions, it is generally advisable to discuss currently approved treatment options such as Mounjaro/ Wegovy/ Ozempic with our doctor rather than delaying care while waiting for investigational medicines.

Key Takeaway

Retatrutide represents an important area of ongoing research in obesity medicine because it targets three hormone pathways involved in appetite, blood sugar regulation, and energy metabolism.

Although early clinical studies are encouraging, retatrutide remains investigational and is not approved for routine clinical use in Malaysia at the time of writing. Retatrutide is 'NOT' registered with Malaysia's Drug Control Authority (DCA). It is illegal to sell or import in the country. An available option would still be Mounjaro (Tirzepatide is a dual GIP and GLP-1 receptor agonist). Drop by for a consultation to see if this is right for you.

For individuals seeking support with weight management, the most appropriate approach is a personalised assessment with a qualified healthcare professional. Current evidence-based treatments, together with nutrition, physical activity, behavioural support, and regular medical follow-up, remain the foundation of effective obesity care. Considering Mounjaro for diabetes & weight management? Always seek advice from an authorised healthcare professional. Our doctors will assess your suitability, discuss potential benefits and risks, and determine whether this treatment is appropriate for your individual needs.